A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

NCT03546621 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis D Infection With Hepatitis B

Interventions

DRUG: Myrcludex B
DRUG: Myrcludex-B
DRUG: Myrcludex-B
DRUG: Tenofovir

Sponsor

Hepatera Ltd.

Collaborators

[object Object]